PD64-02 REAL LIFE EXPERIENCE WITH THE REZUM SYSTEM FOR BENIGN PROSTATIC HYPERPLASIA

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology III1 Apr 2018PD64-02 REAL LIFE EXPERIENCE WITH THE REZUM SYSTEM FOR BENIGN PROSTATIC HYPERPLASIA Daniel Mollengarden, Kenneth Goldberg, Daniel Wong, and Claus Goerg Roehrborn Daniel MollengardenDaniel Mollengarden More articles by this author , Kenneth GoldbergKenneth Goldberg More articles by this author , Daniel WongDaniel Wong More articles by this author , and Claus Goerg RoehrbornClaus Goerg Roehrborn More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.2974AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Convective radiofrequency water vapor thermal therapy with the Rezum system is a relatively new treatment for benign prostatic hyperplasia (BPH). We present results from a single surgeon in an office setting, including efficacy by prostate volume and patient satisfaction data. METHODS A retrospective review was performed on 129 patients who underwent the Rezum procedure by a single surgeon. All patients were at least four months out from treatment. International prostate symptom scores (IPSS), maximum flow rates (Qmax), residual urine volumes, medication usage, and adverse events were monitored. A scripted patient questionnaire was administered over the phone to obtain quality of life and satisfaction data. RESULTS Mean IPSS improved from a baseline of 18.3 to 6.9 and Qmax from 10.5 to 16.8 mL/sec at 3-6 months out (figure 1a). Improvements were independent of starting IPSS, treatment of a median lobe, and prostate size which measured up to 86 cc (figure 1b). There was a 17% prostate volume reduction on TRUS and 14% based on PSA levels. The most common adverse events were urinary tract infections (17%) and transient urinary retention (14%) (table 1). Ninety percent of patients stopped all BPH medications. Questionnaires revealed 86% of patients would recommend the procedure to a friend, and 77% and 74% were either satisfied or very satisfied with the procedure and its results, respectively (figure 2). CONCLUSIONS Rezum radiofrequency thermal therapy offers a minimally invasive option for BPH management with moderate improvement in symptoms and flow rate. The results appear to be independent of prostate size or presence of a median lobe, and patients are largely satisfied. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e1219-e1220 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Daniel Mollengarden More articles by this author Kenneth Goldberg More articles by this author Daniel Wong More articles by this author Claus Goerg Roehrborn More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...